Melatonin Gummies for Kids: The Overdosing Problem

Pediatric melatonin use in the United States has climbed sharply over the past decade. A 2023 cross-sectional survey found that about 1 in 5 U.S. children aged 5–9 had used melatonin in the previous 30 days, and about 1 in 5 preteens (ages 10–13) used it daily (Hartstein 2024 PMID 38109115). Most of this growth has come from gummy products that look like candy and are framed as "natural." The safety picture is more complicated than the marketing suggests.

The Mislabeling Problem

A 2023 JAMA letter (Cohen 2023 PMID 37039797) analyzed 25 melatonin gummy products sold at major U.S. retailers. 22 of the 25 contained a quantity of melatonin that was more than 10% off the stated label dose — the threshold the U.S. Pharmacopeia considers acceptable. Actual melatonin content ranged from 74% to 347% of the labeled dose. One product labeled 1.5 mg per gummy contained nearly 9 mg. Five of the products also contained CBD, which was not always disclosed on the label. This matters in children because the natural nocturnal rise in endogenous melatonin is on the order of 0.05–0.1 mg over the course of the night. Commercial dosing starts at 0.5–1 mg, already 5–20 times physiological levels — and a mislabeled gummy at 6× the stated dose can take a child far above any studied range.

Poison Control Data

CDC and AAPCC data show pediatric melatonin ingestion calls to U.S. Poison Control Centers rose 530% between 2012 and 2021 — from 8,337 to 52,563 calls (Lelak 2022 PMID 35679177). About 83% of those calls were for children aged 5 and under. Over the 10-year period, more than 4,000 children were hospitalized after a melatonin ingestion, with two pediatric deaths reported. The trajectory of calls closely tracks the growth in gummy products. AAPCC has continued to flag melatonin as a top-five reason for pediatric exposure calls in 2023–2024 (AAPCC 2024 Annual Report).

What Pediatric Guidance Recommends

The American Academy of Pediatrics and the American Academy of Sleep Medicine both recommend that behavioral sleep interventions — consistent bedtimes, wind-down routines, dark and cool rooms, screen-free time before bed — be tried first for childhood insomnia (Bruni 2023 European consensus PMID 36739840). For children with autism spectrum disorder or attention-deficit/hyperactivity disorder where behavior strategies are not enough, short-term, low-dose melatonin (0.5–1 mg as a starting dose, ideally an immediate-release tablet rather than a gummy) under pediatric supervision can be reasonable. Effects of long-term pediatric melatonin use on puberty and growth are not yet well studied, which is the main reason expert groups urge caution.